155 related articles for article (PubMed ID: 10911377)
1. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma.
Hara T; Tsurumi H; Takemura M; Goto H; Yamada T; Sawada M; Takahashi T; Moriwaki H
Am J Hematol; 2000 Aug; 64(4):257-61. PubMed ID: 10911377
[TBL] [Abstract][Full Text] [Related]
2. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Sasaki K; Umeda M
Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
[TBL] [Abstract][Full Text] [Related]
3. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma: higher concentrations in angioimmunoblastic T-cell lymphoma.
Yufu Y; Choi I; Hirase N; Tokoro A; Noguchi Y; Goto T; Uike N; Kozuru M
Am J Hematol; 1998 Aug; 58(4):334-6. PubMed ID: 9692400
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of TNF alpha and TNF receptor superfamily members in lymphoid neoplasia.
Metkar SS; Naresh KN; Manna PP; Srinivas V; Advani SH; Nadkarni JJ
Am J Hematol; 2000 Oct; 65(2):105-10. PubMed ID: 10996826
[TBL] [Abstract][Full Text] [Related]
5. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
6. [Measurement of soluble Fas in patients with hematological malignancy].
Liu X; Qi Z; Luo L; Zhang X
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(2):171-3, 176. PubMed ID: 11938782
[TBL] [Abstract][Full Text] [Related]
7. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
10. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
11. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans.
Lenzlinger PM; Marx A; Trentz O; Kossmann T; Morganti-Kossmann MC
J Neuroimmunol; 2002 Jan; 122(1-2):167-74. PubMed ID: 11777556
[TBL] [Abstract][Full Text] [Related]
12. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
13. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
14. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
Armitage JO; Vose JM; Linder J; Weisenburger D; Harrington D; Casey J; Bierman P; Sorensen S; Hutchins M; Moravec DF
J Clin Oncol; 1989 Dec; 7(12):1783-90. PubMed ID: 2585020
[TBL] [Abstract][Full Text] [Related]
16. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
18. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
19. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
20. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
Kawahito K; Misawa Y; Fuse K
Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]